Resource Library
Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies.
Related Resources
June 22, 2020
A STAT3-selective targeted protein degrader decreases the immune-suppressive tumor microenvironment and drives anti-tumor activity in preclinical models
American Association for Cancer Research (AACR) Virtual Annual Meeting II
Other
Read More
December 7, 2019
Small molecule-induced, selective STAT3 degradation leads to anti-tumor activity in STAT3-dependent heme malignancies
American Society of Hematology (ASH) Annual Meeting
Other
Read More
October 26, 2019
Discovery of KYM-003, a potent and selective STAT3 degrader with anti-tumor activity in heme malignancies
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Other
Read More
June 18, 2019
IRAK4 degraders for MYD88 mutant lymphoma
International Conference on Malignant Lymphoma (ICML)
Other
Read More
March 29, 2019
KYM-001, first-in-class oral IRAK4 protein degraders, induce tumor regression in a xenograft model of MYD-88 mutant ABC DLBCL alone and in combination with BTK inhibition
American Association for Cancer Research (AACR) Annual Meeting
Other
Read More
December 1, 2018
Targeted degradation of IRAK4 protein via heterobifunctional small molecules for treatment of MYD88 mutant lymphoma
American Society of Hematology (ASH) Annual Meeting
Other
Read More